Drug Trial Radar · NCT00957047
Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy
Last checked: Nov 20, 2026Latest source record: Mar 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
395
Actual
Start
Jul 2004
Primary completion
Aug 2006
Study completion Jan 2008
Sponsor
- Lead sponsor
- Bial - Portela C S.A.Industry
- Sponsor type
- Industry
- First posted
- Aug 12, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the efficacy of eslicarbazepine acetate once-daily at doses of 400 mg, 800 mg and 1200 mg compared with placebo as adjunctive therapy in patients with refractory partial epilepsy over a 12-week maintenance period. Patients who complete Part I may enter a 1-year open-label extension.
Conditions
- Partial Epilepsy
Interventions
eslicarbazepine acetateDrug
oral tablets
placeboDrug
once daily placebo comparator
ESL - Part IIDrug
Eslicarbazepine acetate was supplied as scored 800-mg tablets for daily oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PART I - Seizure FrequencyTime frame: 12-week maintenance period
- PART II - Nº of Treatment-Emergent Adverse Events (TEAE)Time frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bial - Portela & Cª, S.A.
Trofa, Coronado (S.Romão E S. Mamede), Portugal
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.